Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118

Three Presentations Highlight Clinical and Preclinical Studies

Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118

<0> The Yates NetworkKathryn Morris, +1-845-635-9828 </0>

, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

The results presented in these posters will encompass clinical and preclinical data that highlight the potential of the company’s drug candidates for respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF). The schedule and details of the presentations are as follows:

, Inc. is a biotechnology company developing and commercializing a novel inhaled dry powder drug platform to create a new generation of inhaled therapeutics. The platform, called iSPERSE™ (inhaled small particles easily respirable and emitted), enables drugs to be delivered in inhaled dry powders with unique properties for high drug loading and highly efficient dispersibility and delivery to the airways. iSPERSE can create dry powder formulations with virtually any drug substance, including small molecules, biologics and multi-drug combinations, as well as the company’s proprietary iCALM™ (inhaled Cationic Airway Lining Modulators) inhaled therapies. Pulmatrix’s lead iCALM drug candidate, PUR118, is in human clinical efficacy studies in patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The Company is pursuing both proprietary and partnered applications for iCALM and iSPERSE. For additional information about Pulmatrix, please visit .

iCALM™ and iSPERSE™ are trademarks of Pulmatrix, Inc.

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.